Please check your internet connection and try again.
# Hepamerz (L-Ornithine L-Aspartate)
## Overview
Hepamerz is a combination of the amino acids L-ornithine and L-aspartate. It is used in the management of hyperammonemia, particularly in patients with liver cirrhosis. It is believed to facilitate the detoxification of ammonia in the liver and peripheral tissues.
## Primary Indications
* **Hepatic encephalopathy:** To reduce elevated blood ammonia levels in patients with liver cirrhosis.
## Adult Dosing
* **Intravenous (IV):** Typically administered as a continuous infusion. Common starting doses range from **10 grams to 30 grams per 24 hours**, diluted in an appropriate IV fluid (e.g., dextrose 5% or 10%, Ringer's lactate). The maximum recommended daily dose is generally **40 grams**. Infusion rate should be carefully controlled, often starting slow and titrating based on ammonia levels and patient response.
* **Oral:** Dosing typically ranges from **3 grams to 6 grams, three times daily**. Some sources suggest up to **18 grams per day** in divided doses.
## Pediatric Dosing
* There is **limited established pediatric dosing** for L-ornithine L-aspartate. Dosing in children should be guided by specialist recommendations and should be carefully individualized based on the child's condition, ammonia levels, and weight.
## Dose Adjustments
* No specific dose adjustments are routinely recommended for renal or hepatic impairment, as the drug is primarily used in patients with hepatic dysfunction. However, careful monitoring of ammonia levels and clinical status is crucial.
## Contraindications
* Severe renal insufficiency (creatinine clearance < 25 mL/min) may be a contraindication due to potential accumulation of amino acids.
* Known hypersensitivity to L-ornithine or L-aspartate.
## Adverse Effects
* **Common:** Nausea, vomiting, abdominal discomfort.
* **Less common:** Diarrhea, headache, dizziness, muscle pain, allergic reactions.
* **Rare:** Exacerbation of hepatic encephalopathy in some cases, though this is more likely due to underlying disease progression or other factors.
## Key Drug Interactions
* **Barbiturates and CNS Depressants:** May mask the therapeutic effect of ammonia-lowering agents by sedating the patient.
* **Sulfa drugs:** Concurrent administration may lead to crystalluria, although this is more a concern with individual amino acids.
## Monitoring
* **Serum ammonia levels:** Frequent monitoring is essential to assess efficacy and guide dosing.
* **Electrolytes and renal function:** Monitor periodically, especially in patients with comorbidities.
* **Clinical signs and symptoms of hepatic encephalopathy:** Assess mental status, neurological function, and other relevant parameters.
## Clinical Pearls
* Hepamerz is not a substitute for supportive care in liver disease.
* The efficacy is directly related to reducing ammonia levels.
* IV administration is generally preferred for acute management of severe hepatic encephalopathy.
* Oral administration may be used for maintenance therapy or milder cases.
---
*This information is intended for healthcare professionals and does not replace the need to consult the official prescribing information and current clinical guidelines before use.*
